Competitive Antagonism of the Mouse 5-Hydroxytryptamine3 Receptor by Bisindolylmaleimide I, a “Selective” Protein Kinase C Inhibitor1
Abstract
We examined the effects of several protein kinase C (PKC) inhibitors on the murine 5-hydroxytryptamine3 (5-HT3) receptor to determine whether they acted directly on the receptor. The 5-HT-evoked currents in Xenopus laevis oocytes expressing the recombinant 5-HT3 receptor were measured with the two-electrode voltage-clamp technique. The PKC inhibitors bisindolylmaleimide I (BIM, GF109203x) and staurosporine, but not calphostin C or chelerythrine, decreased the 5-HT3receptor-mediated currents when coapplied with 5-HT. BIM blocked 0.5 μM 5-HT-elicited currents with an IC50 value of 7 nM, whereas in the presence of 5 μM staurosporine, 42% inhibition of 0.5 μM 5-HT-mediated currents was observed. Increasing concentrations of BIM resulted in a rightward shift of the 5-HT concentration-response curve, without altering efficacy. A Schild plot was generated, which had a slope of −1.01, suggesting competitive antagonism. TheKi value of BIM was determined to be 29 nM. To confirm competitive antagonism, a competitive binding assay was performed on Sf21 insect cells infected with the mouse 5-HT3 receptor cDNA in a baculovirus expression vector. BIM completely displaced binding of the selective 5-HT3receptor antagonist [3H]GR65630. BIM bound to the 5-HT3 receptor with a Ki value of 61 nM, which was slightly less potent than that of the selective 5-HT3 receptor antagonist MDL72222 (27 nM). The PKC inhibitor BIM is a potent competitive antagonist at the 5-HT3 receptor.
Footnotes
-
Send reprint requests to: Dr. Tina K. Machu, Department of Pharmacology, Texas Tech University Health Sciences Center, Lubbock, TX 79430.
-
↵1 This work was supported by National Institute of Alcohol Abuse and Alcoholism Grant AA10561 (to T.K.M.).
- Abbreviations:
- BIM
- bisindolylmaleimide
- 5-HT3
- 5-hydroxytryptamine3
- PKC
- protein kinase C
- PMA
- phorbol-12-myristate-13-acetate
- MBS
- modified Barth’s solution
-
- Received November 3, 1998.
- Accepted February 26, 1999.
- The American Society for Pharmacology and Experimental Therapeutics



